IMC Stock Overview
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Immuron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.08 |
| 52 Week High | AU$0.14 |
| 52 Week Low | AU$0.07 |
| Beta | 1.33 |
| 1 Month Change | -6.98% |
| 3 Month Change | 3.90% |
| 1 Year Change | -40.74% |
| 3 Year Change | -41.82% |
| 5 Year Change | -68.00% |
| Change since IPO | -99.20% |
Recent News & Updates
Shareholder Returns
| IMC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -1.2% | -1.7% | 0.4% |
| 1Y | -40.7% | 9.9% | 3.4% |
Return vs Industry: IMC underperformed the Australian Biotechs industry which returned 9.9% over the past year.
Return vs Market: IMC underperformed the Australian Market which returned 3.4% over the past year.
Price Volatility
| IMC volatility | |
|---|---|
| IMC Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IMC is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: IMC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 5 | Steve Lydeamore | https://www.immuron.com.au |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
Immuron Limited Fundamentals Summary
| IMC fundamental statistics | |
|---|---|
| Market Cap | AU$18.22m |
| Earnings (TTM) | -AU$2.85m |
| Revenue (TTM) | AU$765.19k |
23.8x
P/S Ratio-6.4x
P/E RatioIs IMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMC income statement (TTM) | |
|---|---|
| Revenue | AU$765.19k |
| Cost of Revenue | AU$241.69k |
| Gross Profit | AU$523.50k |
| Other Expenses | AU$3.38m |
| Earnings | -AU$2.85m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 68.41% |
| Net Profit Margin | -373.01% |
| Debt/Equity Ratio | 0% |
How did IMC perform over the long term?
See historical performance and comparison